Kura Oncology (FRA:KUR) OCF Margin %: -470.06% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:KUR Kura Oncology Inc FRA:KUR
36 GF Score
Price €9.84
! 7 Warning Signs
View Full Analysis

What is Kura Oncology OCF Margin %?

Kura Oncology FRA:KUR -5.38% 36 OCF Margin % is -470.06% as of Mar. 2026. GuruFocus rates FRA:KUR with a GF Score™ of 36/100. The stock has 7 warning signs investors should review. Among 950 Biotechnology companies, Kura Oncology ranks worse than 54.84% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Kura Oncology's Cash Flow from Operations for the three months ended in Mar. 2026 was €-74.26 Mil. Kura Oncology's Revenue for the three months ended in Mar. 2026 was €15.80 Mil. Therefore, Kura Oncology's OCF Margin % for the quarter that ended in Mar. 2026 was -470.06%.

As of today, Kura Oncology's current OCF Yield % is -8.06%.

The historical rank and industry rank for Kura Oncology's OCF Margin % or its related term are showing as below:

FRA:KUR' s OCF Margin % Range Over the Past 10 Years
Min: -94.93   Med: 77.18   Max: 249.28
Current: -110.11

During the past 12 years, the highest OCF Margin % of Kura Oncology was 249.28%. The lowest was -94.93%. And the median was 77.18%.

FRA:KUR's OCF Margin % is ranked worse than
54.84% of 950 companies
in the Biotechnology industry
Industry Median: -64.565 vs FRA:KUR: -110.11

Kura Oncology OCF Margin % Related Terms

Kura Oncology OCF Margin % Historical Data

* Premium members only.

The historical data trend for Kura Oncology's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kura Oncology OCF Margin % Chart

Kura Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 249.28 -94.93

Kura Oncology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -509.82 -188.23 -388.56 676.47 -470.06

FRA:KUR vs REPL, AVTX, SANA: OCF Margin % Comparison

For the Biotechnology subindustry, Kura Oncology's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kura Oncology OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kura Oncology's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Kura Oncology's OCF Margin % falls into.


FRA:KUR
36GF Score
Kura Oncology Inc FRA:KUR
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kura Oncology OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Kura Oncology's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-54.706/57.63
=-94.93 %

Kura Oncology's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-74.264/15.799
=-470.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -470.06% mean?
Kura Oncology (FRA:KUR) has a OCF Margin % of -470.06% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Kura Oncology and its competitors. According to the industry distribution chart, Kura Oncology ranks #521 out of 950 companies in the Biotechnology industry, placing it in the top 54.8%.
Is Kura Oncology's OCF Margin % too high?
Kura Oncology's current OCF Margin % is -470.06%. Based on the distribution chart, Kura Oncology ranks #521 out of 950 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Kura Oncology has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Kura Oncology's OCF Margin % compare to REPL and AVTX?
According to the Biotechnology industry distribution chart, Kura Oncology ranks #521 out of 950 companies for OCF Margin %. This places Kura Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Kura Oncology and its competitors. Kura Oncology's current OCF Margin % is -470.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kura Oncology stock overvalued right now?
Kura Oncology (FRA:KUR) has a current OCF Margin % of -470.06%. The current OCF Margin % is -470.06%. Kura Oncology's overall GF Score™ is 36/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Kura Oncology (FRA:KUR), the current OCF Margin % is -470.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kura Oncology Business Description

Other Exchanges KURA:USA
Address 4930 Directors Place, Suite 500, San Diego, CA, USA, 92121
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
36GF Score

Get the complete analysis for FRA:KUR

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.84
Price